Regeneron Pharmaceuticals REGN shares are trading higher on Tuesday after the company announced it has been awarded a $450 million contract to manufacture and supply REGN-COV2 Anti-Viral Antibody Cocktail.
Regeneron discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis.
Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.
Regeneron shares are trading up 3.69% at $650.40 at time of publication on Tuesday. The stock has a 52-week high of $651.31 and a 52-week low of $271.37.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
